Ozan Pamir bought NAGE once, on Nov 14, 2025
CFO at Niagen Bioscience, Inc.
SEC CIK 0001834681 · Filings on SEC.gov ↗
Ozan Pamir's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
1 filing since Nov 2025, newest first
About Ozan Pamir
Ozan Pamir (born circa 1991), age 34, is the Chief Financial Officer of Niagen Bioscience, Inc. (NAGE), formerly ChromaDex Corp., a company focused on NAD+ research and healthy aging products like Tru Niagen®.( Appointed on October 21, 2024, he oversees corporate finance, accounting, strategic planning, investor relations, and capital markets activities, reporting to CEO Rob Fried.(
Pamir holds a BA in Economics and Finance from McGill University and is a CFA Charterholder.( His career highlights include serving as CFO of 180 Life Sciences (NASDAQ: ATNF) from 2018 to 2024, where he led finance, investor relations, and NASDAQ listing efforts; CFO roles at Unify Pharmaceuticals and Enosi Life Sciences; and Vice President of Investment Banking at Ventum Financial Corp (formerly Echelon Wealth Partners) from 2014 to 2018, specializing in life sciences financing.( As a corporate insider, he recently purchased 6,685 shares of NAGE worth $45,600 on November 14, 2025.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.